ROR1 and B-cell chronic lymphocytic leukemia: Hudecek et al. has reported the first ROR1 CAR-T that utilized anti-ROR1 antibody clone 2A2 and has shown targeted cytotoxicity against primary B-cell chronic leukaemia (CLL) and mantle cell lymphoma (MCL) [11].